CAMBRIDGE, Mass., Sept. 14, 2016 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced the addition of one of the leading tumor immunologists in the country, Dr. Patrick Hwu of the University of Texas MD Anderson Cancer Center, to its Scientific Advisory Board. Dr. Hwu joins Dragonfly co-founders Dr. Tyler Jacks and Dr. David Raulet, as well as Nobel Prize winner Harold Varmus and leading protein engineer Dane Wittrup, in leading the company's scientific research.
"As we seek to use natural killer cells and other cells of the immune system to eliminate cancer, Dr. Hwu's expertise in tumor immunology and different forms of immunotherapy is invaluable in guiding our drug development," stated Dragonfly's co-founder and head of MIT's Koch Institute, Dr. Tyler Jacks. "Dr. Hwu is a renowned immunologist, and we are thrilled to have a person with his specialized expertise on the team."
Dr. Patrick Hwu is the Head of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. He is considered one of the leading tumor immunologists in the country, and a primary force in the development of novel vaccine and adoptive T-cell therapies. Dr. Hwu's laboratory and clinical work have led to insights and advances in the understanding of the interactions between tumors and the immune system, and the development of cellular immunotherapies. He received his degree from The Medical College of Pennsylvania (MCP), Philadelphia, PA, and trained at The Johns Hopkins Hospital and The National Cancer Institute.
"We are at the tip of the iceberg on the potential for immunotherapies to eliminate cancer," said Dr. Hwu. "I have had the pleasure of contributing to a number of T-cell therapies, which I believe are just the beginning of this revolution in science. Dragonfly's novel technology in harnessing NK cells has great potential. I am thrilled to help the company develop novel drugs that can be applied across a wide range of cancer types."
About Dragonfly Therapeutics
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer.
We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.
Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.
SOURCE Dragonfly Therapeutics, Inc.